ClinicalTrials.gg
TerminatedNCT02943447PBC-Phase 2Updated Sep 22, 2020Results posted

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

A Phase 2 interventional study of Cilofexor and Placebo to match cilofexor in Primary Biliary Cholangitis, sponsored by Gilead Sciences. Terminated at 25 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-09-22.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated because of the availability of alternate therapies for primary biliary cholangitis (PBC).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.

Enrollment
8th of 10
71 · median 126
Started
2016
with 1 other
Phase 2
4 of 10
1 open now
Registered
2nd of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 8th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 2nd registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of cilofexor in adults with primary biliary cholangitis (PBC).

03

Conditions studied

  • Primary Biliary Cholangitis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Meets all of the following conditions

    • Definite or probable PBC as defined by at least 2 of the 3 following criteria:

      • Serum alkaline phosphatase (ALP) > the (ULN)
      • Presence of anti-mitochondrial antibodies (AMA) in serum (≥ 1:40 on immunofluorescence)
      • Liver histological findings consistent with PBC including nonsuppurative, destructive cholangitis affecting mainly the interlobular bile and septal bile ducts
    • Serum ALP > 1.67 x ULN and/or total >ULN but ≤ 2 x ULN
    • Ursodeoxycholic acid (UDCA) use at a stable dose for at least 12 months or intolerant of UDCA with no UDCA use for at least 12 months before screening
  • Screening FibroSURE/FibroTest® \< 0.75 unless a historical liver within 12 months of screening does not reveal cirrhosis. In adults with Gilbert's syndrome or hemolysis, FibroSURE/FibroTest will be calculated using direct bilirubin instead of total bilirubin.

Key Exclusion Criteria:

  • (ALT) > 5 x ULN
  • Total bilirubin > 2 x ULN
  • (INR) > 1.2 unless on anticoagulant therapy
  • Other causes of liver disease including viral, metabolic, alcoholic, and other conditions. Participants with hepatic steatosis may be included if there is no evidence of nonalcoholic steatohepatitis (NASH) in the opinion of the investigator or on liver biopsy.
  • Use of fibrates or obeticholic acid within 3 months prior to screening through the end of treatment
  • Cirrhosis of the liver as defined by any of the following:

    • Historical liver biopsy demonstrating cirrhosis (eg, Ludwig stage 4 or Ishak stage ≥ 5)
    • History of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding
    • Liver stiffness > 16.9 kPa by FibroScan®

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Cilofexor 30 mg (Blinded Study Phase)

    Cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.

    Drug: Cilofexor · Drug: Placebo to match cilofexor

  • Experimental
    Cilofexor 100 mg (Blinded Study Phase)

    Cilofexor 100 mg + placebo to match cilofexor 30 mg for 12 weeks.

    Drug: Cilofexor · Drug: Placebo to match cilofexor

  • Placebo comparator
    Placebo (Blinded Study Phase)

    Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.

    Drug: Placebo to match cilofexor

  • Experimental
    Cilofexor (Open Label Extension Phase)

    Following the Blinded Study Phase, eligible participants may have the option to receive open-label cilofexor 100 mg for an additional 96 weeks.

    Drug: Cilofexor

Interventions

  • Tablet(s) administered orally once daily, with food

    Also known as: GS-9674

  • DrugPlacebo to match cilofexor

    Tablet(s) administered orally once daily, with food

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) in the Blinded Study Phase

    Time frame: First dose date up to Week 12 + 30 days

  2. Percentage of Participants Experiencing TEAEs and TESAEs in the Open-Label Extension (OLE) Phase

    Time frame: First dose date in the OLE phase up to last dose date (Maximum: 97.4 weeks) + 30 days

  3. Percentage of Participants Who Experienced Graded Laboratory Abnormalities in the Blinded Study Phase

    Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.

    Time frame: First dose date up to Week 12 + 30 days

  4. Percentage of Participants Who Experienced Graded Laboratory Abnormalities in the OLE Phase

    Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.

    Time frame: First dose date in the OLE phase up to last dose date (Maximum: 97.4 weeks) + 30 days

07

Results

Posted Jan 13, 2020

Participant flow

Participants were enrolled at study sites in United States, Canada, United Kingdom, and Austria. The first participant was screened on 01 December 2016. The last study visit occurred on 4 September 2019.

Blinded Study Phase
Participant flow — Blinded Study Phase
MilestoneCilofexor 100 mgCilofexor 30 mgPlacebo
Started283013
Completed232812
Not completed521
Withdrew: Withdrew consent121
Withdrew: Adverse event300
Withdrew: Investigator's discretion100
Open-Label Extension Phase
Participant flow — Open-Label Extension Phase
MilestoneCilofexor 100 mgCilofexor 30 mgPlacebo
Started232812
Completed532
Not completed182510
Withdrew: Study terminated by sponsor10126
Withdrew: Adverse event473
Withdrew: Lack of efficacy340
Withdrew: Withdrew consent111
Withdrew: Lost to follow-up010

Outcome measures

PrimaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) in the Blinded Study Phase
Time frame:
First dose date up to Week 12 + 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) in the Blinded Study Phase
percentage of participantsBlinded Study Phase: Cilofexor 100 mgBlinded Study Phase: Cilofexor 30 mgBlinded Study Phase: Placebo
TEAEs89.376.784.6
TESAEs03.30
PrimaryPercentage of Participants Experiencing TEAEs and TESAEs in the Open-Label Extension (OLE) Phase
Time frame:
First dose date in the OLE phase up to last dose date (Maximum: 97.4 weeks) + 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing TEAEs and TESAEs in the Open-Label Extension (OLE) Phase
percentage of participantsOLE Phase: From Cilofexor 100 mgOLE Phase: From Cilofexor 30 mgOLE Phase: From Placebo
TEAEs95.789.3100.0
TESAEs4.300
PrimaryPercentage of Participants Who Experienced Graded Laboratory Abnormalities in the Blinded Study Phase

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.

Time frame:
First dose date up to Week 12 + 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Graded Laboratory Abnormalities in the Blinded Study Phase
percentage of participantsBlinded Study Phase: Cilofexor 100 mgBlinded Study Phase: Cilofexor 30 mgBlinded Study Phase: Placebo
Any Graded Laboratory Abnormality85.786.792.3
Grade 4 or above Laboratory Abnormalities03.30
PrimaryPercentage of Participants Who Experienced Graded Laboratory Abnormalities in the OLE Phase

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.

Time frame:
First dose date in the OLE phase up to last dose date (Maximum: 97.4 weeks) + 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Graded Laboratory Abnormalities in the OLE Phase
percentage of participantsOLE Phase: From Cilofexor 100 mgOLE Phase: From Cilofexor 30 mgOLE Phase: From Placebo
Any Graded Laboratory Abnormality91.396.4100.0
Grade 4 or above Laboratory Abnormalities000

Adverse events

Collected over Blinded Study Phase: First dose date up to Week 12 + 30 days; Open-label Extension (OLE) Phase: First dose date in the OLE Phase up to last dose date (Maximum: 97.4 weeks) + 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinded Study Phase: Cilofexor 100 mg0/28 (0%)0/28 (0%)21/28 (75%)
Blinded Study Phase: Cilofexor 30 mg0/30 (0%)1/30 (3.3%)18/30 (60%)
Blinded Study Phase: Placebo0/13 (0%)0/13 (0%)11/13 (84.6%)
OLE Phase: From Cilofexor 100 mg0/23 (0%)1/23 (4.3%)20/23 (87%)
OLE Phase: From Cilofexor 30 mg0/28 (0%)0/28 (0%)25/28 (89.3%)
OLE Phase: From Placebo0/12 (0%)0/12 (0%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventBlinded Study Phase: Cilofexor 100 mgBlinded Study Phase: Cilofexor 30 mgBlinded Study Phase: PlaceboOLE Phase: From Cilofexor 100 mgOLE Phase: From Cilofexor 30 mgOLE Phase: From Placebo
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/280/300/131/230/280/12
AppendicitisInfections and infestations0/281/300/130/230/280/12
Most frequent other events
Showing 10 of 63
Most frequent other events
EventBlinded Study Phase: Cilofexor 100 mgBlinded Study Phase: Cilofexor 30 mgBlinded Study Phase: PlaceboOLE Phase: From Cilofexor 100 mgOLE Phase: From Cilofexor 30 mgOLE Phase: From Placebo
PruritusSkin and subcutaneous tissue disorders13/286/303/134/2311/286/12
DiarrhoeaGastrointestinal disorders4/284/301/131/236/284/12
HeadacheNervous system disorders4/284/304/132/231/280/12
NauseaGastrointestinal disorders3/282/303/133/232/282/12
FatigueGeneral disorders5/282/303/133/234/282/12
ConstipationGastrointestinal disorders2/281/302/132/230/282/12
Gastrooesophageal reflux diseaseGastrointestinal disorders1/280/300/131/230/282/12
InfluenzaInfections and infestations2/280/300/131/230/282/12
NasopharyngitisInfections and infestations4/285/301/133/234/281/12
Urinary tract infectionInfections and infestations2/282/300/132/232/282/12

Baseline characteristics

The Safety Analysis Set included all participants who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cilofexor 100 mgCilofexor 30 mgPlaceboTotal
Mean54 ± 9.857 ± 6.358 ± 5.956 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Cilofexor 100 mgCilofexor 30 mgPlaceboTotal
Female28261266
Male0415
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cilofexor 100 mgCilofexor 30 mgPlaceboTotal
Race — Asian2002
Race — Black or African American0101
Race — White26271366
Race — Not Permitted0101
Race — Other0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cilofexor 100 mgCilofexor 30 mgPlaceboTotal
Ethnicity — Hispanic or Latino1124
Ethnicity — Not Hispanic or Latino26281165
Ethnicity — Not Permitted1102
Region of Enrollment
Region of Enrollment(participants)Cilofexor 100 mgCilofexor 30 mgPlaceboTotal
Canada99321
Austria4217
United States1216735
United Kingdom3328
08

Study locations

25 sites
  • Sacramento, California 95817, United States
  • Aurora, Colorado 80045, United States
  • Lakewood Ranch, Florida 34211, United States
  • Miami, Florida 33136, United States
  • Marietta, Georgia 30060, United States
  • Saint Paul, Minnesota 55114, United States
  • Arlington, Texas 76012, United States
  • Dallas, Texas 75203, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas 77030, United States
  • Charlottesville, Virginia 22908, United States
  • Newport News, Virginia 23602, United States
  • Seattle, Washington 98104, United States
  • Graz, Steiermark 8036, Austria
  • Wien, Vienna 1090, Austria
  • Calgary, Alberta T2N 4Z6, Canada
  • Vancouver, British Columbia V5Z 1M9, Canada
  • Vancouver, British Columbia V6Z 2K5, Canada
  • Winnipeg, Manitoba R3E 0T6, Canada
  • Toronto, Ontario M5G 2C4, Canada
  • Vaughan, Ontario L4L 4Y7, Canada
  • Birmingham, England B215 2GW, United Kingdom
  • London, England NW3 2QG, United Kingdom
  • London, England SE5 9RS, United Kingdom
  • Norwich, England NR4 7UY, United Kingdom
09

References and documents

Publications

  • Kowdley KV, Minuk GY, Pagadala MR, Gulamhusein A, Swain MG, Neff GW, et al. The Nonsteroidal Farnesoid X Receptor (FXR) Agonist Cilofexor Improves Liver Biochemistry in Patients with Primary Biliary Cholangitis (PBC): A Phase 2, Randomized, Placebo-Controlled Trial [Abstract 45]. Hepatology AASLD Abstracts 2019;70 (Suppl 1):31A-2A.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Sep 2019, 33 months.

Results were first posted in Jan 2020, 4 months after primary completion. A results delay was requested in Jun 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2016
First posted
Oct 24, 2016
StartActual
Dec 1, 2016
Primary completionActual
Sep 4, 2019
CompletionActual
Sep 4, 2019
Results delay requested
Jun 3, 2019
Results first posted
Jan 13, 2020
Last update
Sep 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02943447
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 24, 2016
Start date
Dec 1, 2016
Primary completion
Sep 4, 2019
Completion
Sep 4, 2019
Results posted
Jan 13, 2020
Last update
Sep 22, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilofexor

Start the discussion